EUCTR2016-003373-18-DE进行中（未招募）1 期
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously toPatients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD) - Phase 2 Study of ISIS 681257 in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements
- •2. Males or females aged = 18 and = 80 years old at the time of informed consent
- •3. Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or peripheral artery disease
- •4. Lp(a) plasma level = 60 mg/dL
- •5. Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD risk factors
- •6. Patients on the following medications must be on a stable regimen for at least 4 weeks prior to Screening and expected to remain on a stable regimen through the end of the post-treatment follow-up period:
- •a. Lipid lowering drugs (statins, ezetimibe, PCSK9 inhibitors, niacin, fibrates, fish oil or other products containing omega-3 fatty acids (including OTC preparations)
- •b. Antiplatelet drugs
- •c. Testosterone, estrogens, progesterone, growth hormone or progestins
- •7. Females: must be non-pregnant and non-lactating and either;
- •a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy);
- •b. post-menopausal (defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in females = 55 years, 12 months of spontaneous amenorrhea without an alternative medical cause and FSH levels in the postmenopausal range for the laboratory involved);
- •c. Abstinent* or,
- •d. if engaged in sexual relations of child-bearing potential, agree to use 2 highly effective contraceptive methods (refer to Section 6.3.1) from the time of signing the informed consent form until at least 16 weeks after the last dose of Study
- •Drug (ISIS 681257 or placebo)
- •* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of
- •abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception
- •8. Males must be surgically sterile or, if engaged in sexual relations with a female of child-bearing potential, the patient must be using an acceptable contraceptive method (refer to Section 6.3.1) from the time of signing the informed consent form until at least 16 weeks after the last dose of ISIS 681257
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 175
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 95
排除标准
- •1. Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or stroke/transient ischemic attack
- •2. Within 3 months of Screening: coronary, carotid, or peripheral arterial revascularization, major non-cardiac surgery, or lipoprotein apheresis
- •3. Heart failure NYHA class IV
- •4. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg)
- •5. History of acute kidney injury within 12 months of Screening
- •6. Uncontrolled hyper or hypothyroidism
- •7. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day 1
- •8. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B
- •9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated
- •10. Patients with a history of major bleed or high-risk of bleeding diathesis
- •11. Recent history of, or current drug or alcohol abuse
- •12. Known history or presence of systemic allergic or pseudoallergic (drug) reactions
- •13. Hypersensitivity to the active substance or to any of the excipients
- •14. Clinically-significant abnormalities in screening laboratory values that would render a patient unsuitable for inclusion, including the following:
- •a. Urine protein/creatinine ratio (UPCR) = 0.25 mg/mg. In the event of a UPCR above this threshold, eligibility may be confirmed by a quantitative total urine protein measurement of less than 300 mg/24-hr
- •b. Urine albumin/creatinine ratio (UACR) = 100 mg/g. In the event of a UACR above this threshold, eligibility may be confirmed by a quantitative total urine albumin measurement of less than 150 mg/24-hr
- •c. Estimated GFR less than 60 mL/min as determined by the Chronic Kidney Disease-Epidemiological Collaboration (CKD-EPI) Equation for creatinine clearance
- •d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.0 x ULN
- •e. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be = 3 mg/dL
- •f. Alkaline phosphatase (ALP) > ULN
- •g. Platelet count less than LLN
- •15. Use of warfarin, direct thrombin inhibitors or factor Xa inhibitors
- •16. Treatment with another investigational drug, biological agent, or device within 1 month of Screening, or 5 half-lives of investigational agent, whichever is longer
- •17. Treatment with any non-Ionis oligonucleotide (including small interfering ribonucleic acid [siRNA]) at any time or prior treatment with an Ionis oligonucleotide or siRNA within 9 months of screening. Patients that have previously received only 1 dose of an Ionis oligonucleotide as part of a clinical study may be included as long as = 4 months has elapsed since dosing
- •18. BMI > 40 kg/m2
- •19. Blood donation of 50-499 mL within 30 days of Screening or of > 499 mL within 8 weeks of screening
- •20. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator
- •21. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the Study
研究者
相似试验
进行中（未招募）
1 期
A controlled study to evaluate the safety and the effectiveness of different doses and dosing regimens of ISIS 681257 for the reduction of plasma Lp(a) levels in patients with hyperlipoproteinemia(a) and established Cardio Vascular Disease.EUCTR2016-003373-18-DKAkcea Therapeutics, Inc.270
进行中（未招募）
1 期
A controlled study to evaluate the safety and the effectiveness of different doses and dosing regimens of ISIS 681257 for the reduction of plasma Lp(a) levels in patients with hyperlipoproteinemia(a) and established Cardio Vascular Disease.Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)MedDRA version: 19.1Level: LLTClassification code 10020668Term: HyperlipoproteinemiaSystem Organ Class: 100000004861MedDRA version: 19.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2016-003373-18-NLIonis Pharmaceuticals, Inc.270
已完成
2 期
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)NL-OMON47033Akcea Therapeutics, Inc.11
进行中（未招募）
1 期
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's DiseaseMild Alzheimer's diseaseMedDRA version: 20.0Level: LLTClassification code: 10001896Term: Alzheimer's disease Class: 10029205CTIS2022-501918-55-00Abbvie Deutschland GmbH & Co. KG240
进行中（未招募）
1 期
RIST4721 in Subjects with Palmoplantar PustulosisEUCTR2021-003029-31-HUAristea Therapeutics Inc.156